Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31680
Title: Real-World Effectiveness of Lipid-Lowering Medications on Outcomes after Stroke: Potential Implications of the New-User Design.
Austin Authors: Olaiya, Muideen T;Andrew, Nadine E;Dalli, Lachlan L;Ung, David;Kim, Joosup;Cadilhac, Dominique A;Wood, Peter;May, Janet;Clissold, Ben;Kilkenny, Monique F
Affiliation: Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
The Florey Institute of Neuroscience and Mental Health
Division of Medicine, Queensland Health, Brisbane, Queensland, Australia.
Latrobe Regional Hospital, Traralgon West, Victoria, Australia.
Issue Date: 2022
Date: 2022
Publication information: Neuroepidemiology 2022
Abstract: Observational studies are increasingly being used to provide evidence on the real-world effectiveness of medications for preventing vascular diseases, such as stroke. We investigated whether the real-world effectiveness of treatment with lipid-lowering medications after ischemic stroke is affected by prevalent-user bias.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31680
DOI: 10.1159/000526071
ORCID: 
Journal: Neuroepidemiology
Start page: 365
End page: 372
PubMed URL: 35863320
ISSN: 1423-0208
Type: Journal Article
Subjects: Adherence
Bias
Mortality
Outcomes
Secondary prevention
Stroke
Australia/epidemiology
Stroke/drug therapy
Stroke/epidemiology
Lipids/therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Oct 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.